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Cortistatin (CST) is a neuropeptide, which binds with high affinity all somatostatin (SS) receptor subtypes and shows high
structural homology with SS itself. A receptor specific for CST only, i.e., not recognized by SS, has been recently described in
agreement with data reporting that not all CST actions are shared by SS. Interestingly, CST but not SS also binds ghrelin
receptor (GHS-R1a) in vitro, suggesting a potential interplay between CST and ghrelin system. The aim of this study was to
investigate in humans the endocrine and metabolic activities of human CST-17 in comparison with rat CST-14 that has
previously been shown to exert the same endocrine actions of SS in healthy volunteers. To this aim, in six healthy male
volunteers (age [median, 3rd–97th centiles]: 28.5; 23.6–34.3 years; Body Mass Index: 23.5; 21.0–25.1 kg/m2), we studied the
effects of human CST-17 (2.0 lg/kg/h iv over 120 min), rat CST-14 (2.0 lg/kg/h iv over 120 min) and SS-14 (2.0 lg/kg/h iv over
120 min) on: (a) spontaneous GH, ACTH, PRL, cortisol, insulin and glucose levels; (b) the GH responses to GHRH (1.0 lg/kg
iv at 0 min); (c) the GH, PRL, ACTH, cortisol, insulin and glucose responses to ghrelin (1.0 lg/kg iv at 0 min). CST-17
inhibited (p < 0:01) basal GH secretion to the same extent of CST-14 and SS-14. Spontaneous PRL, ACTH and cortisol se-
cretion were not significantly modified by CST-17, CST-14 or SS-14. CST-17 as well as CST-14 and SS-14 also inhibited
(p < 0:05) spontaneous insulin secretion to a similar extent. None of these peptides modified glucose levels. The GH response to
GHRH was inhibited to the same extent by CST-17 (p < 0:01), CST-14 (p < 0:01) and SS-14 (p < 0:05). The ghrelin-induced
GH response was higher than that elicited by GHRH (p < 0:01) and inhibited by CST-17 (p < 0:05) as well as by CST-14
(p < 0:05) and SS-14 (p < 0:01). The PRL, ACTH and cortisol responses to ghrelin were unaffected by CST-17, CST-14 or SS-
14. On the other hand, the inhibitory effect of ghrelin on insulin levels was abolished by CST-17, CST-14 or SS-14 (p < 0:05)
that, in turn, did not modify the ghrelin-induced increase in glucose levels. In conclusion, this study demonstrates that human
CST-17 and rat CST-14 exert the same endocrine activities of SS in humans. The endocrine actions of human and rat CST
therefore are likely to reflect activation of classical SS receptors.
 2004 Elsevier Ltd. All rights reserved.
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Cortistatin (CST) is a neuropeptide expressed mainly
in the cortex and hippocampus and, more recently, also
found in peripheral tissues such as stomach, kidney,
immune system and pancreas [1–7]. Interestingly, pre-* Corresponding author. Tel.: +39-011-633-4336/4317; fax: +39-011-
664-7421.
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doi:10.1016/j.ghir.2004.04.003pro-CST shows high structural homology with pre-
pro-somatostatin (-SS) and generates two mature
products, CST-14 and CST-29 in rat [1,2] and two,
CST-17 and CST-29, in human [1–4].
SS exerts its multiple biological effects via membrane-
bound receptors of which five subtypes have been cloned
[8,9]. CST-17, CST-14 and CST-29 bind all SS receptor
subtypes with an affinity close to that of SS and therefore
were expected to have similar biological activities [3,4,10].
However, the existence of specific receptors able to bind
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not all CST actions overlap with those of SS [4,10–12].
Moreover, even when co-expressed in the same neurons,
CST and SS are regulated by different stimuli [2,4,13].
In agreement with this hypothesis, a previously
orphan G-protein coupled receptor, named MrgX2,
expressed in dorsal root ganglions, testis, small intes-
tine, spinal cord, pancreas, lung, heart, thymus and
colon, has been recently described as being able to
selectively bind both CST-17 and CST-14 but not SS
[14].
On the other hand, in human tissues, CST-17 as well
as CST-14, but not SS, bind the GH secretagogues re-
ceptor (GHS-R), an endogenous ligand of which is
ghrelin [15–17].
Ghrelin is an acylated 28 amino-acid peptide mostly
synthesized in the stomach but also expressed in several
other central and peripheral endocrine and non-endo-
crine tissues [16,18,19]. Ghrelin exerts several central
and peripheral endocrine and non-endocrine actions
including a stimulatory effect on somatotroph, lacto-
troph and corticotroph secretion and a modulatory in-
fluence on insulin secretion and glucose metabolism
[16,18–20].
Evidence that CST displaces ghrelin binding from its
receptor would have predicted that CST, differently
from SS, has some interaction with ghrelin system [17].
Notice that the MrgX2 has been shown specific for CST
but is unable to bind GHS [14].
Indeed, rat CST-14 has already been demonstrated to
be an active peptide in humans and in rats in whom it
displays similar endocrine actions to those of SS-14
[17,21–24].
The activities of human CST isoforms in humans,
however, have never been investigated so far. As one
single amino-acid mutation is enough to completely
change the biological profile of a peptide [25], we de-
cided to compare the endocrine actions of human CST
with those of rat CST and SS-14 in healthy young vol-
unteers. Specifically, we studied the effects of human
CST-17 on: (a) spontaneous GH, ACTH, PRL, cortisol,
insulin and glucose levels; (b) the GH responses to
GHRH; (c) the GH, PRL, ACTH, cortisol, insulin and
glucose responses to ghrelin.2. Subjects and methods
Six healthy young male volunteers [median; 3rd–97th
centiles] (age: 28.5; 23.6–34.3 years; Body Mass Index:
23.5; 21.0–25.1 kg/m2) were studied.
All subjects gave their written informed consent to
participate in the study which had been approved by an
independent Ethical Committee.
All subjects underwent the following testing sessions
in random order at least three days apart:2.1. Study 1
(1.a) Saline;
(1.b) CST-17 (2.0 lg/kg/h iv over 120 min from 0 to
+120 min);
(1.c) CST-14 (2.0 lg/kg/h iv over 120 min from 0 to
+120 min);
(1.d) SS-14 (2.0 lg/kg/h iv over 120 min from 0 to +120
min).
2.2. Study 2
(2.a) GHRH (1.0 lg/kg iv at 0 min);
(2.b) Ghrelin (1.0 lg/kg iv at 0 min);
(2.c) GHRH (1.0 lg/kg iv at 0 min) +CST-17 (2.0 lg/
kg/h iv over 120 min from )30 to +90 min);
(2.d) GHRH (1.0 lg/kg iv at 0 min) +CST-14 (2.0 lg/
kg/h iv over 120 min from )30 to +90 min);
(2.e) GHRH (1.0 lg/kg iv at 0 min) + SS-14 (2.0 lg/kg/h
iv over 120 min from )30 to +90 min);
(2.f) Ghrelin (1.0 lg/kg iv at 0 min) +CST-17 (2.0 lg/
kg/h iv over 120 min from )30 to +90 min);
(2.g) Ghrelin (1.0 lg/kg iv at 0 min) +CST-14 (2.0 lg/
kg/h iv over 120 min from )30 to +90 min);
(2.h) Ghrelin (1.0 lg/kg iv at 0 min) + SS-14 (2.0 lg/kg/
h iv over 120 min from )30 to +90 min);
After an overnight fast, testing sessions began in the
morning at 08:30–09:00 h, 30 min after an indwelling
catheter had been placed into an antecubital vein of the
forearm kept patent by slow infusion of isotonic saline.
None of the subjects were under treatment with any
drug. Blood samples were taken every 15 min from )15
up to +150 min in sessions (1.a)–(1.d). Blood samples
were taken every 15 min from )30 up to +120 min in
sessions (2.a)–(2.h).
GH levels were assayed in all the sessions. PRL,
ACTH, cortisol, insulin and glucose levels were assayed at
each time point in sessions (1.a)–(1.d), (2.b), (2.f)–(2.h).
Serum GH levels (lg/l; 1 lg/l¼ 45.4 pmol/l) were
measured in duplicate by immunoradiometric assay
(hGH-CTK IRMA, SORIN Biomedica, Saluggia,
Italy). The sensitivity of the assay was 0.15 lg/l. The
inter- and intra-assay coefficients of variation were
2.9–4.5% and 2.4–4.0%, respectively.
Serum PRL levels (lg/l; 1 lg/l ¼ 43.5 pmol/l) were
measured in duplicate by immunoradiometric assay
(PRL-CTK, IRMA, SORIN Biomedica, Saluggia, It-
aly). The sensitivity of the assay was 0.5 lg/l. The inter-
and intra-assay coefficients of variation ranged from
3.9% to 6.8% and from 3.3% to 7.5 %, respectively.
Plasma ACTH levels (pg/ml; 1 pg/ml¼ 0.2202 pmol/l)
were measured by immunoradiometric assay (ACTH,
Nichols Institute Diagnostic, San Juan Capistrano, CA,
USA). The sensitivity of the assay was 1 pg/ml. The
ranges of inter- and intra-assay coefficients of variation
were 2.4–8.5% and 3.9–9.9%, respectively.
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Fig. 1. Median, 3rd and 97th centiles of GH and insulin AUC during
saline or CST-17 (2.0 lg/kg/h iv) or CST-14 (2.0 lg/kg/h iv) or SS-14
(2.0 lg/kg/h iv) administration in six normal subjects.
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measured in duplicate by radioimmunoassay (CORT-
CTK 125, IRMA, SORIN Biomedica, Saluggia, Italy).
The sensitivity of the assay was 4.0 lg/l. The inter- and
intra-assay coefficients of variation ranged from 6.6% to
7.5% and from 3.8% to 6.6%, respectively.
Serum insulin levels (mU/l; 1 mU/l¼ 7.175 pmol/l)
were measured in duplicate by immunoradiometric as-
say (INSIK-5, SORIN Biomedica, Saluggia, Italy). The
sensitivity of the assay was 2.5 0.3 mU/l. The inter-
and intra-assay coefficients of variation were 6.2–10.8%
and 5.5–10.6%, respectively.
Plasma glucose levels (mg/dl; 1 mg/dl¼ 0.05551
mmol/l) were measured by gluco-oxidase colorimetric
method (GLUCOFIX, Menarini Diagnostici, Florence,
Italy).
All samples from an individual subject were analyzed
together.
The hormonal responses are expressed as delta or
absolute values or areas under curves (AUCs) calculated
by trapezoidal integration.
After demonstration by Shapiro–Wilk W test that
data were not Gaussian distributed, statistical analysis
was carried out using non-parametric ANOVA (Fried-
man test) and then Wilcoxon test, as appropriate.
The results are expressed as median, 3rd and 97th
centiles.3. Results
3.1. Study 1
No significant changes of GH (AUC0
0!1200 : 40.1;
22.7–432.6 lgmin/l), PRL (AUC00!1200 : 596.3; 495.2–
782.4 lgmin/l), insulin (AUC00!1200 : 1608.0; 1 399.8–2
107.6 mUmin/l) and glucose (AUC00!1200 : 8606.3; 8
077.9–10102.5 mgmin/dl) levels were observed during
saline administration. On the other hand, a significant
(p < 0:05) trend toward decrease of spontaneous ACTH
(AUC0
0!1200 : 2256.0; 1813.3–2686.8 pgmin/l) and cor-
tisol (AUC0
0!1200 : 14 812.1; 11836.2–16927.9 lgmin/l)
levels was observed.
CST-17 inhibited spontaneous GH secretion
(AUC0
0!1200 : 3.7; 1.6–8.0 lgmin/l, p < 0:01) to the
same extent of CST-14 (AUC0
0!1200 : 5.6; 4.6–10.8
lgmin/l; p < 0:01) and of SS-14 (AUC00!1200 : 9.7; 1.8–
18.2 lgmin/l; p < 0:01) (Fig. 1).
Spontaneous PRL, ACTH and cortisol secretion were
not significantly modified by CST-17, CST-14 or SS-14
administration (data not shown).
CST-17 also inhibited (p < 0:05) spontaneous insulin
secretion (AUC0
0!1200 : 839.3; 837.1–1 117.0 mUmin/l)
with a similar extent than CST-14 (AUC0
0!1200 : 912.7;
426.2–1 759.7 mUmin/l; p < 0:05) and SS-14
(AUC0
0!1200 : 789.7; 447.0–1529.1 mUmin/l; p < 0:01)(Fig. 1). Significant and similar rebound increases of
insulin levels after infusion withdrawal of either CST-17
(Dpeak135!150 above time 1200: 13.8; 11.6–16.1 mU/l;
p < 0:05) or CST-14 (Dpeak135!150 above time 1200:
14.4; 6.85–15.4 mU/l; p < 0:05) or SS-14 (Dpeak135!150
above time 1200: 12.3; 1.5–58.4 mU/l; p < 0:05) were
observed.
CST-17, CST-14 and SS-14 did not modify basal
glucose levels (data not shown).
3.2. Study 2
CST-17 infusion inhibited the GH response to
GHRH (AUC0!90: 140.3; 49.3–530.8 vs. 969.7; 600.1–3
617.0 lgmin/l; p < 0:01) to the same extent of CST-14
(AUC0!90: 282.0; 164.4–364.3 lgmin/l; p < 0:01) and
SS-14 (AUC0!90: 226.5; 65.2–299.3 lgmin/l; p < 0:05).
A significant rebound effect on GH levels after infusion
withdrawal of either CST-17 (Dpeak105!120 above
time 900: 8.6; 5.4–21.7 lg/l; p < 0:05) or CST-14
(Dpeak105!120 above time 900: 5.2; 1.5–9.6 lg/l; p < 0:05)
or SS-14 (Dpeak105!120 above time 900: 1.3; 0.4–12.3 lg/
l; p < 0:05) were observed even after the GHRH tests
(Fig. 2).
Ghrelin induced a GH increase (AUC0!90: 5350.5;
2442.7–9151.8 lgmin/l; p < 0:01) that was higher
(p < 0:01) than that elicited by GHRH. CST-17 inhib-
ited (p < 0:05) the GH response to ghrelin (AUC0!90:
2165.3; 1859.3– 3212.9 lgmin/l) to the same extent of
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Fig. 3. Median, 3rd and 97th centiles of the insulin responses to ghrelin
(1.0 lg/kg iv as a bolus at 00) alone or in coadministration with CST-17
(2.0 lg/kg/h iv from )300 to +900) or CST-14 (2.0 lg/kg/h iv from )300
to +900) or SS-14 (2.0 lg/kg/h iv from )300 to +900) in 6 normal subjects.
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Fig. 2. Median, 3rd and 97th centiles of the GH responses to GHRH
(1.0 lg/kg iv as a bolus at 00) or ghrelin (1.0 lg/kg iv as a bolus at 00)
alone or in coadministration with CST-17 (2.0 lg/kg/h iv from )300 to
+900) or CST-14 (2.0 lg/kg/h iv from )300 to +900) or SS-14 (2.0 lg/kg/
h iv from -300 to +900) in 6 normal subjects.
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p < 0:05) and SS-14 (AUC0!90: 2374.9; 107.5–3086.2
lgmin/l; p < 0:01), making them similar to that to
GHRH alone (Fig. 2).
Unlike GHRH, no rebound effect on GH levels was
observed after infusion withdrawal of either CST-17 or
CST-14 or SS-14 (Fig. 2).
The PRL, ACTH and cortisol responses to ghrelin
were not significantly modified by CST-17, CST-14 or
SS-14 administration (data not shown).
Ghrelin administration also inhibited spontaneous
insulin secretion (DAUC0!90: )183.0; )408.2 to )110.0
mUmin/l; p < 0:01). The inhibitory effect of ghrelin on
insulin levels was almost abolished by CST-17
(DAUC0!90: )73.5; )102.4–155.6 mUmin/l; p < 0:05),
CST-14 (DAUC0!90: )40.5; )129.7–92.61 mUmin/l;
p < 0:05) or SS-14 (DAUC0!90: )3.4; )94.1–51.5
mUmin/l; p < 0:05) co-administration (Fig. 3).
A significant rebound effect on insulin levels after
infusion withdrawal of either CST-17 (Dpeak105!120
over time 900: 16.8; 14.5–34.1 mU/l; p < 0:05) or CST-14
(Dpeak105!120 over time 900: 13.9; 10.7–19.1 mU/l;
p < 0:05) or SS-14 (Dpeak105!120 over time 900: 13.7;
7.4–24.9 mU/l; p < 0:05) were observed even after the
ghrelin tests (Fig. 3).On the other hand, ghrelin also induced an increase
in glucose levels (DAUC0!90: 600.0; 224.7–3087. 6
mgmin/dl; p < 0:01) that was not modified by either
CST-17 (817.5; 295.8–866.9 mgmin/dl), CST-14
(DAUC0!90: 420.0; 30.3–941.7 mgmin/dl) or SS-14
(DAUC0!90: )82.5; )716.2–1608.5 mgmin/dl) infusion.
3.3. Side effects
A transient facial flushing was observed in three
subjects after the administration of GHRH. Four sub-
jects felt a peculiar sudden increase in appetite after
ghrelin administration. CST as well as SS administration
elicited no side effect.4. Discussion
The results of the present study show for the first time
that human CST-17 exerts endocrine and metabolic
activities in humans. Specifically, our present data
demonstrate that CST-17 shares with CST-14 and SS-14
the same inhibitory effect on spontaneous insulin
secretion as well as on spontaneous and GHRH- or
ghrelin-stimulated GH secretion in humans.
As previously reported for CST-14 and SS-14 [23], the
GH-releasing activity of ghrelin is partially resistant also
to CST-17 that, however, does not modify the stimula-
tory effect of ghrelin on both lactotroph and cortico-
troph secretion. An inhibitory effect on insulin secretion
is recorded also after the acute administration of ghrelin
that, however, does not modify that of CST-17, CST-14
and SS-14. On the other hand, CST-17 as well as CST-
14 and SS-14, does not modify the ghrelin-induced
increase in glucose levels.
CST-17 is a neuropeptide able to bind all SS receptors
subtypes with high affinity because of a marked struc-
tural homology with SS itself [3,4,10]. Our previous
386 C. Gottero et al. / Growth Hormone & IGF Research 14 (2004) 382–387studies showed that in humans CST-14 displays the
classical effects of SS-14 inhibiting to the same extent
both spontaneous and GHRH-, ghrelin- or hexarelin-
stimulated GH secretion as well as spontaneous insulin
and ghrelin secretion [17,22,23]. An inhibitory action of
CST-14 on GH secretion similar to that of SS-14 has
also recently been demonstrated in rats [23].
The effects of the administration of the human CST-
17 form had never been studied so far and it was in-
teresting to verify whether this molecular form shares or
not the same actions as rat CST and as native somato-
statin. The similar high affinity of CST-17, -14, and -29
to SS receptors as well as to the GHS receptor suggested
similar biologic activity but this was not necessarily
obvious since the mutation of one single amino acid is
enough to completely change the biological activity of a
peptide [4,10,25].
Our present findings show that CST-17, like CST-14
and SS-14, almost abolishes the GH response to GHRH
but only blunts the stimulatory effect of ghrelin on GH
secretion, in agreement with previous reports showing
that ghrelin, which acts, at least partially, via functional
antagonism of SS activity, is refractory to the inhibitory
effect elicited by the activation of SS receptors [19,22].
On the other hand, at least in these experimental
conditions, CST-17 does not modify the lactotroph and
corticotroph responsiveness to ghrelin, in agreement
with previous data showing that the activation of SS
receptors does not influence the lactotroph and corti-
cotroph responses to hexarelin, a synthetic GHS, as well
as to ghrelin [19].
Moreover, CST-17, like CST-14 and SS-14 infusion,
clearly inhibits insulin secretion which, though to a
lower extent, is also reduced by the acute administration
of ghrelin [20]. Interestingly, ghrelin administration
during CST-17, CST-14 or SS infusion does not modify
their inhibitory action on insulin levels; these findings
suggest that the negative influence of acute ghrelin ad-
ministration on beta cell secretion might be mediated by
enhanced somatostatinergic activity [20]. In agreement
with this hypothesis, a clear interplay between ghrelin
and SS secretion has already been reported. In fact,
native SS as well as synthetic SS analogues markedly
inhibit ghrelin secretion [21,26–28] and, on the contrary,
the acute ghrelin administration increases circulating SS
levels [29].
The present study shows again that the acute ad-
ministration of ghrelin raises glucose levels and shows
that this effect is not abolished by CST-17, CST-14 or SS
infusion. The hyperglycemic effect of ghrelin is unlikely
to be explained by variations of insulin or glucagon se-
cretion and more likely reflects a direct action at the
hepatic level [20,30].
In conclusion, this study demonstrates that human
CST-17 and rat CST-14 exert the same endocrine activ-
ities as SS in humans, likely reflecting their commonactivation of SS receptors. The activation of SS receptors
seems to functionally mask the ability of CST-17 as well
as of CST-14, to bind with high affinity the GHS-R too
and thus to show some peculiar interaction with ghrelin
receptor and activity. In order to clarify this point,
studies with a new CST analogue that does not show any
binding affinity to SS receptors but maintains its ability
to bind the GHS-R are currently being carried out.Acknowledgements
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